- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Hitachi Medical warns of first-half loss
Hitachi Medical expects to report a net loss of $5.67 million for the half-year ended Sept. 30. The company said that despite strong U.S. sales of MRI and diagnostic ultrasound systems, CT and ultrasound sales in Japan have been weak. Hitachi had
Hitachi Medical expects to report a net loss of $5.67 million for the half-year ended Sept. 30. The company said that despite strong U.S. sales of MRI and diagnostic ultrasound systems, CT and ultrasound sales in Japan have been weak.
Hitachi had projected a profit of $3.02 million for the period. The firm said group sales would likely reach $451 million, some $54.44 million short of the original projection.
A spokesperson for the Hitachi Medical Corporation of America said the ultrasound division in the U.S. had exceeded its sales goals in the past few months. She said the company plans new product introductions at the RSNA show.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
